MNPR MONOPAR THERAPEUTICS Expansion Plans 8-K Filing 2024 - License Agreement Monopar Therapeutics has entered into a License Agreement with Alexion Pharmaceuticals for the exclusive rights to develop and commercialize ALXN-1840, a drug for Wilson disease, involving an upfront payment of $4 million and 387,329 shares, with potential milestone payments of up to $94 million.Get access to all SEC 8-K filings of the MONOPAR THERAPEUTICS